Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.

Erica Hlavin Bell,Peixin Zhang,Edward G. Shaw,Jan C. Buckner,Geoffrey R. Barger,Dennis E. Bullard,Minesh P. Mehta,Mark R. Gilbert,Paul D. Brown,Keith J. Stelzer,Joseph P. McElroy,Jessica Fleming,Cynthia Timmers,Aline Paixão Becker,Andrea L. Salavaggione,Ziyan Liu,Kenneth D. Aldape,David Brachman,Stanley Z Gertler,Albert Murtha,Christopher J. Schultz,David G. Johnson,Nadia Laack,Grant K. Hunter,Ian Crocker,Minhee Won,Arnab Chakravarti

Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.

2020

PURPOSENRG Oncology/RTOG 9802 (ClinicalTrials.gov Identifier: NCT00003375) is a practice-changing study for patients with WHO low-grade glioma (LGG, grade II), as it was the first to demonstrate a ...

Keywords:

Low-Grade Glioma
Vincristine
Internal medicine
Procarbazine
Medicine
Lomustine
Glioma
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations